

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>C07D 241/04, 403/12 A61K 31/495</b>	A1	(11) International Publication Number: <b>WO 91/04250</b> (43) International Publication Date: <b>4 April 1991 (04.04.91)</b>
(21) International Application Number: <b>PCT/EP90/01059</b>		(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).
(22) International Filing Date: <b>2 July 1990 (02.07.90)</b>		
(30) Priority data: <b>408,020 15 September 1989 (15.09.89) US</b>		Published <i>With international search report.</i>
(71) Applicant: <b>SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN [DE/DE]; Müllerstr. 170/78, D-1000 Berlin 65 (DE).</b>		
(72) Inventors: <b>LUMMA, William, Carl, Jr. ; 25 Newman Road, M.R.1, Pennsburg, PA 18073 (US). MORGAN, Thomas, Kenneth, Jr. ; 47 Sherman Avenue, Morris Plains, NJ 07950 (US). PHILLIPS, Gary, Bruce ; 1591 Topside, Wharton, NJ 07885 (US).</b>		

(54) Title: **2-SUBSTITUTED-1(4)-ARYL PIPERAZINES AND THE PROCESS FOR THEIR PREPARATION**

(57) Abstract

This invention relates to novel 2-substituted-1(4)-aryl piperazines and to a process for their preparation. The compounds of this invention have been found to have cardiovascular, primarily antiarrhythmic effects.

## **DESIGNATIONS OF "DE"**

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

### ***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TC	Togo
				US	United States of America

5

2-SUBSTITUTED-1(4)-ARYL PIPERAZINES AND  
THE PROCESS FOR THEIR PREPARATION

Field of the Invention

This invention relates to novel 2-substituted-1(4)-aryl piperazines and their  
10 pharmaceutically acceptable salts. Further encompassed by the invention is a  
novel process for the production of the compounds. The compounds of the  
invention exhibit a variety of cardiovascular properties primarily of an  
antiarrhythmic nature for which pharmaceutical compositions are proposed.

15


General Description of the Invention

Composition-of-Matter Aspect

In its composition-of-matter aspect, this invention relates to novel 2-  
20 substituted-1(4)-aryl piperazines and the pharmaceutically acceptable salts thereof.

Compounds encompassed by the invention are of the following Formula I:

2



wherein R is hydrogen, lower alkyl or benzyl; and

10

R<sub>1</sub> and R<sub>2</sub> are the same or independently hydrogen, lower alkyl, lower alkoxy or halogen.

Z is  $\text{NR}_3\text{C=O}$ ,  $\text{NR}_3\text{CH}_2$ ,  $\text{OCH}_2$ ,  $\text{NR}_3-$ ,  $\text{O}-$  or  $\text{NR}_3\text{SO}_2-$  and

15

Q is  $(\text{C}_1\text{-C}_4)\text{SO}_2\text{NR}_4-$  or

R<sub>3</sub> is hydrogen, lower alkyl, allyl or loweralkoxyloweralkyl and

20

R<sub>4</sub> is hydrogen or methyl.

Included in the descriptors of the compounds of Formula I is the proviso that when R<sub>4</sub> is methyl then  $\text{CH}_2\text{-Z}-\text{C}_6\text{H}_4\text{-Q}$  must be in the 2 position of Formula I.

25

As used herein, the term "lower" when used conjunctively with alkyl or alkoxy or use of the term (C<sub>1</sub>-C<sub>4</sub>) shall each represent a straight or branched chain alkyl of one to four carbon atoms as for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, or tertiary butyl. The term halogen shall mean chlorine, bromine, fluorine or iodine.

Contemplated as part of this invention are the pharmaceutically acceptable salts of the compounds of Formula I. These most generally are acid in nature and formed with inorganic or organic acids. Illustrative but not restrictive examples of such acids include hydrochloric, hydrobromic, sulfuric, phosphoric, citric, acetic, propanoic, benzoic, naphthalenecarboxylic, oxalic, succinic, malic, maleic, adipic, lactic, tartaric, salicylic, methanesulfonic, 2-hydroxyethanesulfonic, toluenesulfonic, benzenesulfonic, camphorsulfonic and ethanesulfonic acids.

It is to be understood that the definition of the compounds of Formula I encompasses all possible stereoisomers and mixtures thereof which possess the activities discussed below. In particular, it encompasses the geometrical and optical isomers and the racemic modifications thereof which possess the indicated activity.

The compounds of the invention exhibit cardiovascular effects most especially antiarrhythmic effects. As antiarrhythmic agents the compounds can be classified as Class II, Class III or combination Class III/II agents.

Preferred classes of compounds which exhibit the combination Class III/II effects are those of Formula I:

wherein R and R<sub>4</sub> are hydrogen and  $-\text{CH}_2\text{-Z}-\text{C}_6\text{H}_4\text{-O}$  is in the ② position.

5

Preferred classes of compounds which primarily exhibit the Class III effect are those of Formula I wherein:

- a) R<sub>4</sub> is hydrogen and  $-\text{CH}_2\text{-Z}-\text{C}_6\text{H}_4\text{-O}$  is in the ① position or

10

- b) R is not hydrogen and R<sub>4</sub> is hydrogen.

Preferred classes of compounds which primarily exhibit the Class II effect are those of Formula I wherein R is hydrogen, R<sub>4</sub> is methyl and  $-\text{CH}_2\text{-Z}-\text{C}_6\text{H}_4\text{-O}$  is in the ② position.

15

The following compounds are some of those which serve to exemplify the various composition-of-matter and/or process aspects of the invention as described herein.

20

- 1) 4-[(Methylsulfonyl)amino]-N-[[4-phenyl-1-(phenylmethyl)piperazin-2-yl]methyl]benzamide.

25

- 2) N-[4-[[[4-(3,5-Dichlorophenyl)piperazin-2-yl]methoxy]methyl]phenyl]methanesulfonamide.

3) N-[[4-(3,5-Dimethoxyphenyl)piperazin-2-yl]methyl]-4-[(ethylsulfonyl)amino]benzenesulfonamide.

5 4) N-[[4-(3-Bromo-5-methoxyphenyl)piperazin-2-yl]methyl]-4-(1H-imidazol-1-yl)benzenesulfonamide.


10 5) N-[[4-(2,6-Dichlorophenyl)piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]-N-(2-propenyl)benzenesulfonamide.

6) 4-Ethoxyphenyl-N-(2-methoxyethyl)-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-2-piperazinemethanamine.

15 7) N-[[4-(3-Chlorophenyl)piperazin-2-yl]methyl]-N-methylethyl-4-[(methylsulfonyl)amino]benzamide.


PROCESS ASPECT

The novel 2-substituted-1(4)-aryl piperazines of this invention are prepared  
20 essentially as illustrated in the following Schemes A-E. These schemes are  
inclusive of a novel process for the regioselective preparation of an intermediate  
used in the process.

Scheme A


15

The route outlined in Scheme A illustrates the preparation of the diamines used in the process, wherein an appropriately substituted aniline [a] is reacted with a haloacetyl halide (chloride or bromide) in a solvent such as methylene chloride or acetic acid in the presence of a base such as pyridine, triethylamine or sodium acetate at a temperature of from about -20°C to 50°C. The resulting haloacetylanilide [b] is then reacted with between two and six equivalents of a primary amine either neat or in a lower alkanol at a temperature between 20 and 120°C to provide [c]. The compound [c] is reacted with lithium aluminum hydride or borane dimethylsulfide in an ethereal solvent at a temperature between 20 and 100°C to provide the diamine [d]. Alternatively, the diamine [d] may be prepared by the method of Lis and Marisca (Syn. Commun. 1988, 18, 45).

Scheme B

The regioselective routes outlined in Scheme B are an improvement of the method of Toja, et al. (E. Toja, A. Omodei-Sale, N. Corsico, Farmaco Ed. Sci. 1984, 39, 450) which details the reaction of N-phenyl-N'-phenylmethyl-1,2-ethanediamine with 2,3-dibromopropionic acid methyl ester to obtain a 7:3 mixture of 1-phenyl-4-phenylmethyl-2-piperazinecarboxylic acid methyl ester and 4-phenyl-1-phenylmethyl-2-piperazinecarboxylic acid methyl ester.


The route outlined in Scheme B illustrates the regioselective preparation of 4-aryl-1-(substituted)-2-piperazinecarboxamide [e] or 1-aryl-4-(substituted)-2-piperazinecarbonitrile [f]. A suitably substituted diamine [d] is combined with 2,3-dibromopropanamide [g] in a suitable solvent such as dimethylformamide, acetonitrile, or toluene in the presence of a base such as pyridine, triethylamine, or diisopropylethylamine at a temperature from about 80 to 150°C. The progress of the reaction is followed by thin-layer chromatography. Upon completion, the reaction mixture is partitioned between a suitable organic solvent (ethyl acetate, ether, or methylene chloride) and aqueous base. The organic layer is separated and dried ( $MgSO_4$ ,  $Na_2SO_4$ , or  $CaSO_4$ ) and evaporated. Purification by recrystallization or flash chromatography provides the amide [e]. The nitrile [f] may be prepared in an analogous fashion by using 2,3-dibromopropancarbonitrile [h] or 2-chloroacrylonitrile. The amides [i and j] may be prepared in an analogous fashion by using the appropriately substituted amide [k] and separating the two regioisomers by either recrystallization or chromatography.

Scheme C

10

The route in Scheme C illustrates the preparation of the compounds of the invention wherein Z is NR<sub>3</sub>CO, NR<sub>3</sub>SO<sub>2</sub>, NR<sub>3</sub>CH<sub>2</sub>. An appropriately substituted piperazine [l] is reacted with lithium aluminum hydride or borane dimethylsulfide in an ethereal solvent at a temperature between 20 and 100° to provide the 2-piperazinemethanamine [m]. This compound is then reacted with the appropriate activated acid to provide [n]. The typical activated acids used are acid chlorides and mixed anhydrides. An alternate route to [n] is to react the appropriate amine with trimethylaluminum followed by the appropriate methyl ester per Weinreb (Tetrahedron Lett. 1977, 4171). The benzyl group is removed in a manner according to the art and compound involved. For compounds in which hydrogenolysis is acceptable, the typical conditions are hydrogenation over palladium hydroxide or palladium on carbon in the presence of acid at 30-50 psi of hydrogen to provide [o]. For removal of a 3,4-dimethoxybenzyl group, reaction of [n] with aqueous acid (sulfuric acid, hydrobromic acid, trifluoroacetic acid, and/or acetic acid) at temperatures between 40 and 150°C provides [o]. The benzamide [o] is converted to the amine [p] by reduction with lithium aluminum hydride or borane dimethylsulfide as described earlier.

11

Scheme D


/2

The route in Scheme D illustrates the preparation of the compounds of the invention wherein Z is NH. Reduction of the nitro group in an appropriately substituted 2-piperazinecarboxamide [q] with stannous chloride in a solvent such as ethanol or ethyl acetate at a temperature between 30-100°C gives the corresponding aniline [r]. Conversion of this aniline to the various groups described in the invention are as follows. To obtain an imidazole the aniline is reacted with ammonium acetate, aqueous glyoxal, and the appropriate aldehyde per the conditions of Debus (ANN. 1858, 107, 204). To obtain a sulfonamide the aniline is reacted with the appropriate alkylsulfonyl chloride or alkylsulfonic anhydride in a solvent such as acetonitrile, propionitrile, or methylene chloride at a temperature of 0-80°C. To obtain a sulfonamide in which R<sub>4</sub> is methyl, the appropriate sulfonamide is reacted with a base such as sodium hydroxide, sodium methoxide or potassium t-butoxide and a methylating agent such as iodomethane or dimethylsulfate in an alkanol at a temperature of 0-100°C. Reaction of the resulting amide [s] as described in Scheme C provides compounds of the invention [u].

20

25

13

Scheme E

25

The route in Scheme E illustrates the preparation of the compounds of the invention wherein Z is  $\text{--O--}$ ,  $\text{--OCH}_2\text{--}$ ,  $\text{--NR}_3\text{CH}_2\text{--}$ , and  $\text{--NR}_3\text{--}$ . Hydrolysis of the amide or nitrile [v] under standard conditions provides the acid [w].

5 Reduction of the acid under the conditions of Brown using borane dimethylsulfide provides the alcohol [x]. Reaction of the alcohol [x] with sodium hydride and 4-fluoronitrobenzene or 4-nitrobenzyl bromide in a solvent such as toluene, dimethylformamide, or dimethylsulfoxide at a temperature between 0-100° provides the corresponding ethers ([y], Z=O or OCH<sub>2</sub>). Reaction 10 of the amine [m] in an analogous manner provides the tertiary amines ([y], Z=NR<sub>3</sub> or NR<sub>3</sub>CH<sub>2</sub>). Reaction of the resulting compound [y] in a manner as described in Scheme D provides compounds of the invention.

15 Compounds of the invention contain asymmetric carbon atoms and may be prepared as their optically active or racemic components. Preparation of the enantiomers may be accomplished where necessary by resolution of the racemate using an optically active acid such as (+) or (-) tartaric acid, (+) or (-) camphorsulfonic acid, etc. or by resolution of an intermediate in a similar manner followed by the completion of the synthesis.

20

#### METHOD-OF-USE AND PHARMACEUTICAL COMPOSITION ASPECT

25 The novel 2-substituted-1(4)-aryl piperazines of this invention and their pharmaceutically acceptable salts are cardiovascular agents particularly antiarrhythmic agents. Most especially within the aegis of cardiovascular

pharmacology some of the compounds are designed to provide a combination beta-adrenergic blockade with electrophysiologic activity to selectively prolong cellular refractoriness. According to the Vaughan Williams classification, such agents would have combination Class II/Class III antiarrhythmic effect. Such 5 combination contains those therapeutic effects attributed to Class II and Class III antiarrhythmic agents singly. Other compounds of the invention demonstrate Class II or Class III antiarrhythmic effects alone.

In the Vaughan Williams classification of antiarrhythmic agents, Class II 10 agents are the anti-adrenergic agents, among these are the so called  $\beta$ -blockers which decrease the sensitivity of the cardiac tissue to catecholamines. The catecholamines in excess can cause electrical instability of the heart. Class II agents are exemplified by propranolol, metoprolol, nadolol, timolol, atenolol, acebutolol and nifradilol. The Class III agents prolong the action potential 15 duration of the heart thus increasing the time interval in which the heart is unexcitable (refractory period) without slowing conduction or changing the excitability of the cardiac cells. These agents have little or no effect on conduction, in fact, they are quite independent of conduction. Such agents are exemplified in the literature by bretylium, amiodarone, clofibrate, melperone and 20 sematilide (the latter compound developed in these laboratories).

Several investigators have demonstrated that the arrhythmia responsible for sudden cardiac death is ventricular fibrillation (VF). VF has been shown to occur via a reentrant mechanism. Reentrant ventricular arrhythmias can occur as 25 a result of abnormalities in conduction and/or refractoriness. In a reentrant

arrhythmia, a single cardiac impulse follows a circular pathway, allowing repeated excitation of the same tissue. One approach to the abolition of such reentrant arrhythmias is to further prolong the refractory period of cardiac cells, such that the impulse, upon returning to its point of origin, is met with refractory tissue and propagation of the impulse is stopped. This is clearly the therapeutic rationale behind the development of agents possessing Class III activity.

Reentrant arrhythmias often are initiated or "triggered" by an appropriately timed premature impulse. In patients, who have had a myocardial infarction, excessive catecholamine levels may be responsible for triggering many arrhythmias which may be associated with sudden cardiac death. In fact, the results of several large, multi-center trials have shown that beta-adrenergic blockers can reduce mortality from sudden cardiac death in post-infarction patients. Presumably, beta-blockers work by decreasing the sensitivity of the heart to catecholamines, and thereby decrease the potential "triggering" event which leads to reentrant ventricular arrhythmias. The overall decrease in mortality from these studies is approximately 25%, suggesting that beta-adrenergic blockade when used alone offers no beneficial antiarrhythmic effect in the remaining majority of post-infarction patients. Clinical data such as these highlight the multiple etiologies present in patients dying of sudden cardiac death and the need for a more "broad spectrum" approach.

One broad spectrum approach is to produce an agent with both Class II and Class III properties. Several investigators have shown that an increase in

sympathetic tone to the heart will shorten refractoriness, an action which can be blocked by beta-adrenergic antagonists. Preliminary data using the selective Class III agent clofilium have shown that its Class III actions are blunted in the setting of enhanced sympathetic tone (Sullivan and Steinberg, 1981).

5 Furthermore preliminary studies performed in conscious dogs in these laboratories suggest a synergistic effect between inhibition of beta-receptors and prolongation of refractoriness. In pilot studies utilizing programmed electrical stimulation (PES) techniques to induce reentrant arrhythmias, a sub-therapeutic dose of sematilide, a Class III agent, was administered and shown not to be efficacious.

10 Subsequent administration of a beta-blocking dose of propranolol (0.5 mg/kg, i.v.) was shown to protect the heart from PES-induced arrhythmias. Previous studies in these laboratories have demonstrated that propranolol when used alone is not efficacious in this model. In animals receiving the combination therapy, ventricular refractory period increased 8% following sematilide and 18% with the addition of propranolol. Propranolol, when used alone at this dose, had no effect on refractoriness. These data suggest a synergistic action between Class III and Class II agents and that modulation of beta-adrenergic tone can enhance the Class III properties of certain agents.

15

20 Sotalol can be considered the prototype drug for agents with both Class II and Class III activity. Experimental and clinical data suggest that the beta-blocking effect of sotalol begins at doses lower or equivalent to doses which produce its Class III actions. Thus, certain of the compounds of this invention are designed to have a more potent Class III action relative to their Class II

potency in order to demonstrate a distinct advantage in the setting of reentrant ventricular arrhythmias.

The compounds of this invention have been tested for their Class III activity via in vitro electrophysiologic testing utilizing standard intracellular microelectrode techniques in the canine cardiac Purkinje fiber. They were then tested for reasonable beta-adrenergic blocking activity as measured in the in vitro screens of isolated papillary muscle (inhibition of the inotropic response to epinephrine) and the beta-adrenergic binding screen (displacement of radiolabelled dihydroalprenolol). They were then assessed in the in vivo model of the pentobarbital anesthetized dog in which the compound was administered intravenously and its Class III (increase in functional refractory period) and Class II (inhibition of isoproterenol response) effects were monitored.

The compounds of this invention exemplified by 4-[(methylsulfonyl)amino]-N-[(4-phenylpiperazin-2-yl)methyl]benzamide, N-[[4-(3-chlorophenyl)piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]benzamide, N-[4-[[[(4-phenylpiperazin-2-yl)methyl]amino]methyl]phenyl]methanesulfonamide, N-[[4-[[[(4-phenylpiperazin-2-yl)methyl]amino]phenyl]methanesulfonamide, N-[[4-(3-methoxyphenyl)piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]benzamide have been analyzed in the foregoing biological procedures and provide the combination Class II/III antiarrhythmic effects.

In essence the compounds of this invention provide the physician with a single chemical entity providing two effects thereby mitigating the problems of:

multiple drug therapy, e.g. side effects, metabolic problems, drug interactions, etc. and the problems in patient compliance - different drugs, different therapeutic regimens.

5           Other compounds of the invention exemplified by 4-[(methylsulfonyl)amino]-N-[(1-phenylpiperazin-2-yl)methyl]benzamide and N-[4-[[[(1-phenylpiperazin-2-yl)methyl]amino]phenyl]methanesulfonamide have been analyzed in the foregoing biological procedures and provide Class III antiarrhythmic effects.

10           Still another group of compounds exemplified by 4-[(methyl)(methylsulfonyl)amino]-N-[(4-phenylpiperazin-2-yl)methyl]benzamide has been analyzed in the foregoing biological procedures and provides the Class II antiarrhythmic effect.

15           Thus, the compounds of the invention are preferably utilized in the treatment of mammalian arrhythmias and most specifically used in the treatment of mammalian arrhythmias in need of combination Class II/III effects, albeit some of the compounds may have Class II or Class III effects alone.

20           In general, the compounds of this invention may be administered orally or parenterally. The dosage administered will depend on the subject being treated, the route of administration and the type and severity of the arrhythmias being prevented or reduced.

The compound to be administered can be formulated by admixing with any of a number of suitable pharmaceutical diluents and carriers such as lactose, sucrose, starch powder, cellulose, calcium sulfate, sodium benzoate and the like. Such formulations can be compressed into tablets or can be encapsulated into 5 gelatin capsules for convenient oral administration. Such a capsule may contain one of the compounds of this invention, for example, 4-[(methylsulfonyl)amino]-N-[(4-phenylpiperazin-2-yl)methyl]benzamide in the amount of about 1 to about 500 mg. Such formulation can be administered orally at the rate of about 1 to 4 capsules per day or more often as needed, depending upon the particular 10 condition and subject being treated.

For parenteral administration a compound of this invention can be formulated as an intramuscular or intravenous medicament but is not limited thereto. In the case of treatment of a patient suffering from severe cardiac 15 arrhythmias, it may be desirable to administer a compound of the invention by intravenous slow bolus in order to effect a rapid conversion to a normal sinus rhythm. The normalized condition can then be maintained by oral administration.

20 The compounds of this invention can be formulated for parenteral administration with any of a number of pharmaceutically acceptable carriers and diluents to constitute an injectable liquid solution. Commonly used diluents and carriers include water or a saline solution, buffered aqueous solutions as well as dispersing and surface active agents if necessary. A typical formulation suited to 25 intravenous or intramuscular administration may contain one of the compounds of

this invention such as 4-[(methylsulfonyl)amino]-N-[(4-phenylpiperazin-2-yl)methyl]benzamide in the amount of about 50 to 150 mg and a solubilizing agent and sufficient sterile water to bring the volume to about 5mL-100mL. Such formulation can be infused at a constant rate or injected one to four times per day or more often depending upon the particular condition of the subject being treated.

It is further contemplated that the compounds of this invention may be formulated into sublingual lozenges or impregnated into fabric appliques for transdermal application.

The invention described hereinabove is illustrated below in the Preparations and Examples, which, however, are not to be construed as limiting the scope of this invention.

15

### PREPARATIONS

#### Preparation 1

20

##### 4-Phenyl-1-(phenylmethyl)-2-piperazinecarboxamide

To dimethylformamide (300 mL) add N-phenyl-N'-phenylmethyl-1,2-ethanediamine (83 g, 0.37 mol), 2,3-dibromopropanamide (90 g, 0.39 mol) and triethylamine (41 g, 0.40 mol). Heat the resulting mixture at 110°C and follow the progress of the reaction by thin-layer chromatography. Upon completion of

the reaction add 1N NaOH until basic and add ethyl ether. Filter the precipitate that forms and recrystallize from 2-propanol to obtain the title compound.

NMR (CDCl<sub>3</sub>): δ = 2.45(m,1), 2.92(m,1), 3.10(dd,1), 3.28(dd,1), 3.40(m, 2), 3.75(m, 1), 3.99(d,1), 5.70(br s,1), 6.90(m,4) and 7.32(m,7)ppm.

5

### Preparation 2

#### 4-Phenyl-1-(phenylmethyl)-2-piperazinemethanamine

To 4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide (28.5 g, 96 mmol) dissolved in tetrahydrofuran (220 mL) add lithium aluminum hydride (9.0 g, 0.24 mol) portionwise. Stir and heat the reaction to reflux. Monitor the progress of the reaction by thin-layer chromatography. Upon completion, slowly add water (9 mL), 2N NaOH (9 ml), and H<sub>2</sub>O (27 mL). Suction filter the slurry through celite and wash the pad with ethyl acetate (500 mL). Remove the solvent in vacuo to give a brown oil. Flash chromatograph the oil on silica (400 g) with 19/1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH to give the title compound.

NMR (CDCl<sub>3</sub>): δ = 2.4(m,1), 2.6(m,1), 2.9(m,3), 3.05(dd,1), 3.15(dd,1), 3.3(m,1), 3.35(d,1), 3.45(d,1), 4.1(d,1), 6.85(t,1), 6.95(d,2) and 7.2-7.4(m,7)ppm.

### Preparation 3

20

#### 4-[(Methylsulfonyl)amino]-N-[[4-phenyl-1-(phenylmethyl)piperazin-2-yl]benzamide hydrochloride

To tetrahydrofuran (100 mL) under nitrogen atmosphere add 4-phenyl-1-(phenylmethyl)-2-piperazinemethanamine (10 g, 35 mmol) followed by 4-[(methylsulfonyl)amino]benzoyl chloride (6.6 g, 28 mmol). When the additions

are complete allow the reaction to stir. Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the reaction, filter the resulting solid and wash the solid with tetrahydrofuran to give the title compound.

5 NMR (DMSO-d<sub>6</sub>): δ = 3.08(s,3), 3.10-3.66(m,5), 3.71(d,1), 3.85-4.10(m,3), 4.32(m,1), 5.15(d,1), 6.88(t,1), 7.00(d,2), 7.28(m,4), 7.39(m,3), 7.70(m,2), 7.95(m,2), 9.02(m,1), 10.22(s,1) and 10.98(br s,1)ppm.

#### Preparation 4

10

##### 1-Phenyl-4-(phenylmethyl)-2-piperazinecarbonitrile

In a manner similar to Preparation 1, react N-phenyl-N'-(phenylmethyl)-1,2-ethanediamine (0.41 g, 1.8 mmol) with 2,3-dibromopropanenitrile (0.77 g, 3.6 mmol) in toluene (5 mL) with triethylamine (0.73 g, 0.72 mmol) to obtain the title compound.

15

NMR (CDCl<sub>3</sub>): δ = 2.40(dt,1), 2.55(dd,1), 3.0(d,1), 3.15(dt,1), 3.3(dt,1), 3.40(d,1), 3.60(d,1), 3.75(d,1), 4.53(br s,1), 7.0(m,3) and 7.3(m,7)ppm.

#### Preparation 5

20

##### 1-Phenyl-4-(phenylmethyl)-2-piperazinemethanamine

In a manner similar to Preparation 2, react 1-phenyl-4-(phenylmethyl)-2-piperazinecarbonitrile (16.6 g, 60 mmol) with lithium aluminum hydride (6.8 g, 180 mmol) to obtain the title compound.

25

NMR (CDCl<sub>3</sub>): δ = 2.3(m,2), 2.8(m,3), 3.1(m,2), 3.3(m,1), 3.48(d,1),

3.60(d,1), 3.7(m,1), 6.8(m,2), 6.90(d,3) and 7.3(m,7)ppm.

Preparation 64-[(Methylsulfonyl)amino]-N-[1-phenyl-4-(phenylmethyl)-  
5 piperazin-2-yl]methyl] benzamide

In a manner similar to Preparation 3, react 1-phenyl-4-(phenylmethyl)-2-piperazinemethanamine (11.1 g, 40 mmol) with 4-[(methylsulfonyl)amino]benzoyl chloride (10.1 g, 43 mmol) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.14(m,2), 2.88(m,2), 3.05(s,3), 3.15(m,1),  
10 3.42(m,2), 3.52(s,2), 3.69(m,1), 4.15(br s,1), 6.65(t,1), 6.95(d,2), 7.18(m,5),  
7.31(t,2), 7.38(d,2), 7.62(d,2), 8.23(br t,1) and 10.08(s,1).

Preparation 715 4-(1H-Imidazol-1-yl)-N-[4-phenyl-1-(phenylmethyl)piperazin-2-yl]-  
methyl]benzamide, [RS]

To N,N-dimethylformamide (200 mL) under nitrogen atmosphere add 4-(1H-imidazol-1-yl)benzoic acid (7.0 g, 37 mmol) and 1,1-carbonyldiimidazole (6.0 g, 37 mmol) and stir for 1 h. Add 4-phenyl-1-(phenylmethyl)-2-piperazinemethanamine (9.5 g, 34 mmol) and stir. Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the reaction remove the solvent in vacuo. To the oil add water (100 mL), a saturated solution of sodium bicarbonate (30 mL) and methylene chloride (200 mL) and stir for 1 h. Separate the layers and extract the aqueous layer with methylene chloride. Concentrate the combined organic layers to give an oil. Flash chromatograph

the oil on silica (1000 g) with a mixture of methylene chloride, methanol, triethylamine (97/2/1). Combine and concentrate the fractions containing product. Recrystallize the solid from ethyl acetate/hexane to provide the title compound.

NMR ( $\text{CDCl}_3$ ):  $\delta = 2.50(\text{m},1)$ ,  $2.88\text{-}3.13(\text{m},4)$ ,  $3.35(\text{m},1)$ ,  $3.51(\text{m},2)$ ,  
5  $3.79(\text{br s},2)$ ,  $4.10(\text{d},1)$ , ca.  $6.6\text{-}8.2(\text{br},1)$ ,  $6.82\text{-}7.02(\text{m},4)$ ,  $7.20\text{-}7.40(\text{m},8)$ ,  $7.45(\text{d},2)$ ,  
 $7.83(\text{d},2)$  and  $7.92(\text{s},1)$ ppm.

### Preparation 8

10 **N-(3-Methoxyphenyl)-N'-(phenylmethyl)-1,2-ethanediamine hydrochloride**

Combine 3-methoxybenzenamine (81.2 g, 0.66 mol) with N-(2-chloroethyl)-benzenemethanamine hydrochloride (45.3 g, 0.22 mol) and heat to 190°C for 13 h. Add methylene chloride to precipitate a solid. Filter the solid and wash with methylene chloride. Triturate the solid with 100 mL of ethanol, 15 filter the solid and wash with ethanol to give the title compound.

NMR ( $\text{DMSO-d}_6$ ):  $\delta = 3.01(\text{br s},2)$ ,  $3.32(\text{s},2)$ ,  $3.62(\text{s},3)$ ,  $4.14(\text{br s},2)$ ,  $5.88\text{-}6.25(\text{m},3)$ ,  $6.95(\text{t},1)$ ,  $7.25\text{-}7.50(\text{m},3)$ ,  $7.58(\text{s},2)$  and  $9.3(\text{br s},2)$ ppm.

### Preparation 9

20

**4-(3-Methoxyphenyl)-1-(phenylmethyl)-2-piperazinecarboxamide**

In a manner similar to Preparation 1, react N-(3-methoxyphenyl)-N'-(phenylmethyl)-1,2-ethanediamine (16 g, 63 mmol) with 2,3-dibromopropanamide (29 g, 126 mmol) and triethylamine (25 g, 0.25 mol) to give the title compound.

NMR (CDCl<sub>3</sub>): δ = 2.4(m,1), 2.94(m,2), 3.07(dd,1), 3.25(dd,1), 3.38(m,2), 3.75(m,1), 3.78(s,3), 3.98(d,1), 5.8(s,1), 6.45(m,2), 6.54(d,1), 7.0(s,1), 7.17(t,1) and 7.3(m,5)ppm.

5

### Preparation 10

#### 4-(3-Methoxyphenyl)-1-(phenylmethyl)-2-piperazinemethanamine

In a manner similar to Preparation 2, react 4-(3-methoxyphenyl)-1-(phenylmethyl)-2-piperazinecarboxamide (0.9 g, 27 mmol) with lithium aluminum hydride (2.1 g, 55 mmol) to give the title compound.

NMR (CDCl<sub>3</sub>): δ = 2.4(m,1), 2.6(m,1), 2.9(m,3), 3.05(dd,1), 3.15(dd,1), 3.31(m,1), 3.35(d,1), 3.45(d,1), 3.72(s,3), 4.1(d,1), 6.32-6.66(m,3), and 7.00-7.46(m,6)ppm.

### Preparation 11

15

#### 4-[(Methylsulfonyl)amino]-N-[4-(3-methoxyphenyl)-1-(phenylmethyl)-piperazin-2-yl]methyl]benzamide dihydrochloride

In a manner similar to Preparation 3, react 4-(3-methoxyphenyl)-1-(phenylmethyl)-2-piperazinemethanamine (3.1 g, 10 mmol) with 4-[(methylsulfonyl)amino]benzoyl chloride (3.3 g, 15 mmol) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 3.08(s,3), 3.10-3.66(m,5), 3.70(s,3), 3.71(d,1), 3.85-4.10(m,3), 4.32(m,1), 5.15(d,1), 6.40-6.62(m,3), 7.18(t,1), 7.31(d,2), 7.49(m,3), 7.74(m,2), 8.00(d,2) and 10.24(s,1)ppm.

25

Preparation 12N-(2-Methoxyphenyl)-2-[(phenylmethyl)amino]acetamide

To ethanol (100 mL) add benzylamine (35 g, 0.33 mol) and 2-chloro-N-(2-methoxyphenyl)acetamide (22 g, 0.11 mol). Stir and heat the reaction at 50°C. Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the reaction remove the precipitate that has formed by suction filtration and discard. Evaporate the filtrate and partition the residue between ethyl acetate and 2N NaOH(aq). Separate the organic layer and dry it over Na<sub>2</sub>SO<sub>4</sub>. Remove the drying agent by filtration and remove the solvent in vacuo. Chromatograph the residue on silica gel (400 g) using hexane/EtOAc (3/1) as eluent to obtain the title compound.

NMR (CDCl<sub>3</sub>): δ = 3.43(s,2), 3.82(s,2), 3.88(s,3), 6.88(dd,1), 6.95(t,1), 7.04(t,1), 7.2-7.4(m,6), 8.44(dd,1) and 9.9(br s,1)ppm.

15

Preparation 13N-(2-Methoxyphenyl)-N'-(phenylmethyl)-1,2-ethanediamine

In a manner similar to Preparation 2, react N-(2-methoxyphenyl)-2-[(phenylmethyl)amino]acetamide (0.31 g, 1.1 mmol) with lithium aluminum hydride (0.09 g, 2.4 mmol) to obtain the title compound.

NMR (CDCl<sub>3</sub>): δ = 2.85(t,2), 3.2(t,2), 3.75(s,2), 3.8(s,3), 4.6(br,1), 6.6(d,1), 6.65(m,1), 6.75(d,1), 6.85(t,1), and 7.2-7.4(m,5)ppm.

25

Preparation 144-(2-Methoxyphenyl)-1-(phenylmethyl)-2-piperazinecarboxamide

In a manner similar to Preparation 1, react N-(2-methoxyphenyl)-N'-  
5 (phenylmethyl)-1,2-ethanediamine (15.4 g, 60.2 mmol) with 2,3-dibromo-  
propanamide (27.7 g, 0.12 mol) to give the title compound.

NMR ( $\text{CDCl}_3$ ):  $\delta = 2.61(\text{m},1)$ ,  $2.92(\text{m},2)$ ,  $3.05(\text{dd},1)$ ,  $3.2(\text{m},1)$ ,  $3.38(\text{m},1)$ ,  
3.45(m,1), 3.61(d,1), 3.85(d,1), 3.85(s,3), 5.6(br,1), 6.87(d,1), 6.95(m,2),  
7.05(m,1), 7.3(m,5), and 7.6(br,1)ppm.

10

Preparation 154-(2-Methoxyphenyl)-1-(phenylmethyl)-2-piperazinemethanamine

In a manner similar to Preparation 2, react 4-(2-methoxyphenyl)-1-  
15 (phenylmethyl)-2-piperazinecarboxamide (4.0 g, 16.6 mmol) with lithium  
aluminum hydride (1.0 g, 26 mmol) to give the title compound.

NMR ( $\text{CDCl}_3$ ):  $\delta = 2.5(\text{t},1)$ ,  $2.65(\text{m},1)$ ,  $2.75(\text{t},1)$ ,  $2.9(\text{m},2)$ ,  $3.0(\text{dd},1)$ ,  
3.2(m,3), 3.4(d,1), 3.85(s,3), 4.1(d,1), 6.8-7.0(m,4) and 7.2-7.4(m,5)ppm.

20

Preparation 16N-[{4-(2-Methoxyphenyl)-1-(phenylmethyl)piperazin-2-yl]methyl}-  
4-[(methylsulfonyl)amino]benzamide hydrochloride

In a manner similar to Preparation 3, react 4-(2-methoxyphenyl)-1-  
25 (phenylmethyl)-2-piperazinemethanamine (3.8 g, 12 mmol) with 4-[(methyl-

sulfonyl)amino]benzoyl chloride (3.2 g, 14 mmol) to give the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 3.08(s,3), 3.0-3.2(m,3), 3.4-3.9(m,5), 3.7(s,3), 4.05(m,1), 4.3(m,1), 5.1(d,1), 6.9-7.1(m,4), 7.3(d,2), 7.5(s,4), 7.75(m,2), 7.95(d,2), 9.0(br,1), 10.2(s,1) and 11.05(br,1)ppm.

5

Preparation 17

4-Phenyl-1-(phenylmethyl)-2-piperazinecarboxylic acid

Suspend 4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide (14.5 g, 49 mmol) in ethylene glycol (400 mL) and add potassium hydroxide (27.5 g, 490 mmol). Heat this mixture to 150°C for 18 h. After this time, remove the solvent in vacuo. Add 6M hydrochloric acid (81.5 mL, 0.49 mol) and water (300 mL) and filter the resultant solid to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.78(m,1), 3.28(m,3), 3.56(m,2), 3.70(m,1), 3.98(d,1), 4.24(d,1), 4.3-6.6(br,1), 6.83(t,1), 6.92(d,2) and 7.15-7.55(m,7)ppm.

Preparation 18

4-Phenyl-1-(phenylmethyl)-2-piperazinemethanol

Suspend 4-phenyl-1-(phenylmethyl)-2-piperazinemethanol (12.2 g, 41 mmol) in tetrahydrofuran (800 mL) and add borane methylsulfide (12.4 mL, 124 mmol) dropwise over 30 minutes under nitrogen. Stir and heat the reaction to reflux and distill off 50 mL of liquid. Continue refluxing this mixture for 3 h. After this time, cool to room temperature and add methanol (100 mL). Allow the reaction mixture to stand at room temperature for 2 h. After this time,

remove the solvent in vacuo. Add ethyl acetate (800 mL) and 1N sodium hydroxide (200 mL) and enough methanol to clarify the solution. Separate the layers, then wash the organic layer with water (200 mL) and remove the solvent in vacuo. Flash chromatograph the residue on flash silica gel with acetonitrile to give the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.27(m,1), 2.55(m,1), 2.68-2.86(m,3), 3.23-3.58(m,4), 3.79(m,1), 4.10(dd,1), 4.71(m,1), 6.75(m,1), 6.90(d,2) and 7.14-7.39(m,7)ppm.

10

Preparation 192-[(4-Nitrophenoxy)methyl]-4-phenyl-1-(phenylmethyl)piperazine

Suspend 4-phenyl-1-(phenylmethyl)-2-piperazinemethanol (7.8 g, 27.6 mmol) in dimethylformamide under nitrogen and add 60% sodium hydride (1.22 g, 30.4 mmol). Stir for 20 h as solid slowly dissolves. Add 1-fluoro-4-nitrobenzene (4.29 g, 30.4 mmol) and stir at room temperature. Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the reaction, add water (100 mL) to the reaction mixture and extract with methylene chloride (2X100 mL). Remove the solvent in vacuo and recrystallize the residue from ethyl acetate/hexanes (1/1) (80 mL) to provide the title compound.

NMR (DMSO-d<sub>6</sub>): δ 2.47(m,1), 2.84(m,1), 3.05(m,1), 3.20(m,1), 3.45(m,1), 3.56(d,1), 4.05(d,1), 4.36(m,1), 4.51(m,1), 6.75(t,1), 6.93(d,2), 7.12-7.43(m,9) and 8.19(d,2)ppm.

Preparation 204-[[4-Phenyl-1-(phenylmethyl)piperazin-2-yl]methoxy]benzeneamine

Dissolve 2-[(4-nitrophenoxy)methyl]-4-phenyl-1-(phenylmethyl)piperazine (7.15 g, 17.7 mmol) in a 1/1 mixture of methanol and ethyl acetate (350 mL) and add tin II chloride dihydrate (20.0g, 88.6 mmol). Stir the mixture and heat the reaction to reflux. Monitor the progress of the reaction by thin-layer chromatography and add more tin II chloride dihydrate as needed. Upon completion of the reaction, pour reaction mixture into water (200 mL) and add 4N sodium hydroxide to pH=12. Extract with a solution of ethyl acetate/methanol (2/1) (2X200 mL). Wash the combined extracts with water (200 mL) and remove the solvent in vacuo. Flash chromatograph the residue on flash silica gel (250 g) with an ethyl acetate/hexanes [gradient (1/1-1/0)] to give the title compound.

NMR ( $\text{CDCl}_3$ ):  $\delta = 2.47(\text{m},1)$ ,  $2.87(\text{m},1)$ ,  $2.97\text{-}3.28(\text{m},3)$ ,  $3.43(\text{br s},2)$ ,  $3.55(\text{m},1)$ ,  $4.02\text{-}4.27(\text{m},3)$ ,  $6.64(\text{d},2)$ ,  $6.76(\text{d},2)$ ,  $6.84(\text{t},1)$ ,  $6.93(\text{d},2)$  and  $7.20\text{-}7.42(\text{m},7)$ ppm.

Preparation 2120 N-[4-[[4-Phenyl-1-(phenylmethyl)piperazin-2-yl]methoxy]phenyl]methanesulfonamide

Dissolve 4-[[4-phenyl-1-(phenylmethyl)piperazine-2-yl]methoxy]benzene-amine (6.28 g, 16.8 mmol) in acetonitrile (100 mL) and add methanesulfonic anhydride (3.22 g, 18.5 mmol). Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the reaction, add water (100 mL),

ethyl acetate (50 mL) and sat. aq. sodium bicarbonate (50 mL). Separate the layers and reextract the aqueous layer with ethyl acetate (75 mL). Wash the combined organic extracts with sat. aq. sodium chloride (75 mL) and remove the solvent in vacuo to give the title compound.

5 NMR (DMSO-d<sub>6</sub>): δ 2.42(m,1), 2.82(m,1), 2.89(2,3), 2.99(m,1), 3.11(m,1), 3.21(m,1), 3.52(d,1), 4.07(d,1), 4.17(m,1), 4.31(m,1), 6.77(t,1), 6.93(d,2), 6.98(d,2), 7.10-7.45(m,9) and 9.37(br s,1)ppm.

### Preparation 22

10

#### 2,3-Dibromo-N-(4-nitrophenyl)propanamide

To N-(4-nitrophenyl)-2-propenamide (58 g, 0.30 mol) suspended in CCl<sub>4</sub> (200 mL) at 0°C add bromine (16.2 g, 0.317 mol) dropwise. Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the 15 reaction, filter the solid to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 3.96-4.14(m,2), 4.85(dd,1), 7.88(d,2), 8.28(d,2), and 11.20(s,1)ppm.

### Preparation 23

20

#### N-(4-Nitrophenyl)-4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide (A)

and

#### N-(4-Nitrophenyl)-1-phenyl-4-(phenylmethyl)-2-piperazinecarboxamide (B)

Add N-phenyl-N'-(phenylmethyl)-1,2-ethanediamine (29 g, 128 mmol), N-25 (4-nitrophenyl)-2,3-dibromopropanamide (45 g, 128 mmol) and triethylamine (36

mL, 255 mmol) to dimethylformamide (100 mL). Stir the mixture and heat the reaction to 105°C. Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the reaction, add 1N NaOH until basic and add diethyl ether (2X300 mL). Filter the resulting precipitate. Add sat. aq. 5 sodium chloride (200 mL) to aqueous layer and extract with 2-propanol (300 mL). Evaporate the solvent from the organic layer and combine the resulting residue and the initial precipitate. Flash chromatograph this mixture on flash silica gel (525 g) with an ethyl acetate/hexanes [gradient (1/3→1/1)] to give both compounds A & B.

10 A - NMR (DMSO-d<sub>6</sub>): δ = 2.38(m,1), 2.94(m,2), 3.19(dd,1), 3.36(m,2), 3.43(d,1), 3.71(d,1), 3.88(d,1), 6.79(t,1), 6.96(d,2), 7.31(m,7), 7.97(d,2), 8.25(d,2) and 10.66(s,1)ppm.

15 B - NMR (DMSO-d<sub>6</sub>): δ = 2.36(td,1), 2.44(dd,1), 2.96(d,1), 3.25(d,1), 3.42(d,1), 3.53(d,1), 3.65(m,1), 3.68(d,1), 4.54(s,1), 6.72(t,1), 6.86(d,2), 7.19(m,7), 7.50(d,2), 8.22(d,2) and 10.49(s,1)ppm.

#### Preparation 24

##### 20 N-(4-Aminophenyl)-4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide

In a manner similar to Preparation 20, react N-(4-nitrophenyl)-4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide (6.85 g, 16.8 mmol) with tin (II) chloride dihydrate (18.5 g, 82 mmol) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.28(m,1), 2.82(m,2), 3.08(m,1), 3.18(m,1), 3.28(d,1), 3.48(m,1), 3.64(m,1), 3.86(d,2), 4.90(s,2), 6.62(d,2), 6.78(t,1), 6.94(d,2), 7.18-7.44(m,4) and 9.6(s,1)ppm.

5

Preparation 25N-[4-[(Methylsulfonyl)amino]phenyl]-4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide

In a manner similar to Preparation 21, react N-(4-aminophenyl)-4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide (5.88 g, 15.2 mmol) with methane-sulfonic anhydride (2.91 g, 16.7 mmol) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.30(m,1), 2.86(m,2), 2.92(s,3), 3.11(t,1), 3.25(dd,1), 3.32(d,1), 3.46(d,1), 3.66(d,1), 3.86(d,1), 6.79(t,1), 6.95(d,2), 7.14-7.44(m,9), 7.63(d,2), 9.57(s,1) and 10.03(s,1)ppm.

15

Preparation 26N-[4-[[[4-Phenyl-1-(phenylmethyl)piperazin-2-yl]methyl]amino]phenyl]-methanesulfonamide

In a manner similar to Preparation 18, react N-[4-[(methylsulfonyl)-amino]phenyl]-4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide (4.1 g, 8.8 mmol) with borane dimethylsulfide (2.65 mL of a 10N solution, 26.5 mmol) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.39(br t,1), 2.83(s,3), 2.8-3.0(m,4), 3.2-3.5(m,5), 4.13(d,1), 5.63(br s,1), 6.60(d,2), 6.80(t,1), 6.95(m,4), 7.20-7.43(m,7) and 9.00(s,1)ppm.

5

Preparation 27N-[4-[(Methylsulfonyl)amino]phenyl]-1-phenyl-4-(phenylmethyl)-2-piperazinecarboxamide

Dissolve N-(4-nitrophenyl)-1-phenyl-4-(phenylmethyl)-2-piperazinecarboxamide (17.7 g, 30.5 mmol) in ethyl acetate (1200 mL) and add tin II chloride dihydrate (34.4 g, 153 mmol). Stir this mixture and heat to reflux. Monitor the progress of the reaction by thin-layer chromatography and add more tin II chloride dihydrate if necessary. Upon completion of the reaction, pour the reaction mixture into crushed ice (1 kg) and neutralize the mixture to pH=8 with sat. aq. sodium bicarbonate. Dilute with ethyl acetate (1000 mL) and filter through celite. Wash the organic layer with sat. aq. sodium chloride and remove the solvent. Flash chromatograph the residue on silica gel (350 g) with an ethyl acetate/hexanes [gradient (1/3-1/1)] to give an oil. Dissolve this oil in acetonitrile (100 mL) and add methanesulfonic anhydride (3.34 g, 19.2 mmol). Warm this mixture to 80°C for 10 min. After this time, cool the mixture to room temperature and add sat. aq. sodium bicarbonate (100 mL) ethyl acetate (100 mL) and water (50 mL). Wash the organic layer with sat. aq. sodium chloride (100 mL) and remove the solvent in vacuo. Recrystallize the residue from ethyl acetate (100 mL) to provide the title compound.

NMR (CDCl<sub>3</sub>): δ = 2.55(m,1), 2.82(m,2), 2.96(s,3), 3.08(dd,1), 3.40(m,2), 3.61(dd,2), 4.33(t,1), 6.26(s,1), 6.92(t,1), 7.05(d,2), 7.13(d,2), 7.22-7.45(m,9) and 9.20(s,1)ppm.

5

Preparation 28N-[4-[[[1-Phenyl-4-(phenylmethyl)piperazin-2-yl]methyl]amino]phenyl]-methanesulfonamide

In a manner similar to Preparation 18, react N-[4-[(methylsulfonyl)-amino]phenyl]-4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide (5.88 g, 12.7 mmol) with borane dimethylsulfide (3.8 mL of a 10N solution, 38 mmol) to give the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.16-3.4(m,2), 2.8(s,3), 2.8-3.05(m,3), 3.14(br t,1), 3.3-3.65(m,4), 3.92(m,1), 5.2(br s,1) 6.46(d,2), 6.72(t,1), 6.89(d,2), 6.93(d,2), 7.15-7.40(m,7) and 8.62(m,1)ppm.

Preparation 29N-[3-[[2-[(Phenylmethyl)amino]ethyl]amino]phenyl]acetamide hydrochloride

Combine N-(3-aminophenyl)acetamide (31 g, 0.206 mol) and N-(2-chloroethyl)benzenemethanamine hydrochloride (17.0 g, 0.083 mol) and heat to 180°C for 1 h. After this time, allow to cool to approximately 85°C and add isopropanol (100 mL) to precipitate a solid. Decant the solvent and dissolve the white residue in refluxing methanol (800 mL). Filter hot and allow the solution

to cool to room temperature. After 2 h, filter the resulting white solid and wash with methanol (50 mL) to give the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.03(s,3), 3.09(br s,2), 3.40(m,2), 4.21(s,2),  
5.88(br,1), 6.32(d,1), 6.76(d,1), 7.02(m,2), 7.47(m,3), 7.59(m,2), 9.33(br,2) and  
9.77(s,1)ppm.

### Preparation 30

#### 4-[3-(Acetylamino)phenyl]-1-(phenylmethyl)-2-piperazinecarboxamide

In a manner similar to Preparation 1, react N-[3-[[2-[(phenylmethyl)-  
amino]ethyl]amino]phenyl]acetamide (25.6 g, 90.4 mmol) with 2,3-  
dibromopropanamide (41.8 g, 180.8 mmol) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ 2.03(s,3), 2.23(m,1), 2.79(m,2), 2.97(m,2), 3.23(d,1),  
3.39(m,1), 3.55(d,1), 5.91(d,1), 6.63(d,1), 7.1(m,2), 7.19(s,1), 7.35(m,6), 7.55(s,1),  
and 9.80(s,1)ppm.

### Preparation 31

#### 4-(3-Aminophenyl)-1-(phenylmethyl)-2-piperazinecarboxamide

To 4-[3-(acetylamino)phenyl]-1-(phenylmethyl)-2-piperazinecarboxamide  
(14.0 g, 39.9 mmol) in methanol (115 mL) add 6N aqueous hydrochloric acid  
(28 mL). Stir the reaction at reflux. Monitor the progress of the reaction by  
thin-layer chromatography. Upon completion of the reaction adjust the pH to 12  
with 4N aqueous NaOH to obtain a white precipitate. Filter the precipitate to  
obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.20(m,1), 2.74(m,2), 2.92(m,2), 3.21(d,1), 3.51(d,1), 3.89(d,1), 4.9(s,2), 6.05(d,1), 6.12(d,1), 6.16(s,1), 6.86(t,1), 7.34(m,6), and 7.50(s,1)ppm.

5

Preparation 324-(3-Aminophenyl)-1-(phenylmethyl)-2-piperazinemethanamine

In a manner similar to Preparation 18, react 4-(3-aminophenyl)-1-(phenylmethyl)-2-piperazinecarboxamide (9.0 g, 30 mmol) with borane dimethylsulfide complex (15 mL, 150 mmol) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.26(m,1), 2.38(m,1), 2.64-2.94(m,5), 3.17-3.6(m,5), 4.09(d,1), 4.86(s,2), 6.05(d,1), 6.15(d,1), 6.17(s,1), 6.85(t,1), 7.28(m,1), and 7.36(m,4)ppm.

15

Preparation 33N-[4-(3-Aminophenyl)-1-(phenylmethyl)piperazin-2-yl]methyl]-4-[[(methylsulfonyl)amino]benzamide]

In a manner similar to Preparation 3, react 4-(3-aminophenyl)-1-(phenylmethyl)-2-piperazinemethanamine (4.8 g, 16 mmol) with 4-[(methylsulfonyl)amino]benzoyl chloride (3.8 g, 16 mmol) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.33(m,1), 2.80(m,4), 3.03-3.24(m,2), 3.08(s,3), 3.36(m,1), 3.45(d,1), 3.72(m,1), 4.16(d,1), 4.88(br s,2), 6.06(d,1), 6.14(d,1), 6.16(s,1), 6.86(t,1), 7.33(m,7), 7.87(d,2), 8.48(t,1) and 10.15(br s,1)ppm.

25

Preparation 34N-[4-[3-(1H-Imidazol-1-yl)phenyl]-1-(phenylmethyl)piperazin-2-yl]methyl]-  
4-[(methylsulfonyl)amino]benzamide

To reagent alcohol (60 mL) at 60°C simultaneously add a solution of N-  
[[4-(3-aminophenyl)-1-(phenylmethyl)piperazin-2-yl]methyl]-4-  
[(methylsulfonyl)amino]benzamide (7.1 g, 14 mmol) and ammonium hydroxide  
(28% aqueous ammonia, 1.94 mL, 29 mmol) diluted to 200 mL with alcohol and  
a solution of aqueous glyoxal (1.9 mL, 17 mmol) and aqueous formaldehyde (1.6  
mL, 22 mmol) diluted to 200 mL with alcohol. Upon completion of the  
additions, monitor the progress of the reaction by thin-layer chromatography.  
Upon completion of the reaction, partition the reaction between ethyl acetate and  
aqueous NaHCO<sub>3</sub>. Separate and dry the organic layer and remove the solvent in  
vacuo. Flash chromatograph the residue on silica with CH<sub>3</sub>CN/NH<sub>4</sub>OH (99/1) to  
obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.35(m,1), 2.80(m,2), 3.08(m,5), 3.32(m,1),  
3.51(m,3), 3.73(m,1), 4.13(d,1), 6.91(d,1), 7.00(d,1), 7.03(s,1), 7.32(m,10),  
7.69(s,1), 7.86(d,2), 8.21(s,1) and 8.29(t,1)ppm.

20

Preparation 35N-(3-Chlorophenyl)-2-[(3,4-dimethoxyphenyl)methyl]aminoacetamide

In a manner similar to Preparation 11, react 2-bromo-N-(3-chlorophenyl)-  
acetamide (4.4 g, 18 mmol) with 3,4-dimethoxybenzenemethanamine (8.7 g, 53  
mmol) to obtain the title compound.

NMR (CDCl<sub>3</sub>): δ = 3.40(s,2), 3.75(s,2), 3.84(s,3), 3.86(s,3), 6.85(m,3), 7.10(d,1), 7.23(m,2), 7.42(d,2) and 7.66(s,1)ppm.

Preparation 36

5

N-(3-chlorophenyl)-N'-(3,4-dimethoxyphenyl)methyl]-1,2-ethanediamine

In a manner similar to Preparation 2, react N-(3-chlorophenyl)-2-[(3,4-dimethoxyphenyl)methyl]amino]acetamide (13.6 g, 40.1 mmol) with lithium aluminum hydride (3.1 g, 81 mmol) to obtain the title compound.

10 NMR (CDCl<sub>3</sub>): δ = 2.90(t,2), 3.22(m,2), 3.77(s,2), 3.86(s,3), 3.88(s,3), 6.41-6.70(m,3), 6.75-6.93(m,3) and 7.08(t,1)ppm.

Preparation 37

15 4-(3-Chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinecarboxamide

In a manner similar to Preparation 1, react N-(3-chlorophenyl)-N'-(3,4-dimethoxyphenyl)methyl]-1,2-ethanediamine (13.3 g, 41 mmol) with 2,3-dibromopropanamide (19.1 g, 166 mmol) to obtain the title compound.

20 NMR (DMSO-d<sub>6</sub>): δ = 2.20(t,1), 2.50(s,1), 2.72-2.98(m,2), 3.06(t,1), 3.25(d,1), 3.49(m,2), 3.60(d,1), 3.75(m,6), 6.72-7.05(m,4), 7.13-7.35(m,2) and 7.52(s,1)ppm.

25

Preparation 384-(3-Chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinemethanamine

5 In a manner similar to Preparation 2, react 4-(3-chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinecarboxamide (6.0 g, 15 mmol) with lithium aluminum hydride (1.2 g, 31 mmol) to obtain the title compound.

NMR ( $\text{CDCl}_3$ ):  $\delta = 2.30\text{-}2.42(\text{m},1)$ ,  $2.50\text{-}2.60(\text{m},1)$ ,  $2.85\text{-}2.96(\text{m},3)$ ,  $3.03\text{-}3.14(\text{m},2)$ ,  $3.25\text{-}3.35(\text{m},2)$ ,  $3.50(\text{d},1)$ ,  $3.90(\text{s},6)$ ,  $4.05(\text{d},1)$ ,  $6.75\text{-}6.92(\text{m},6)$  and  
10  $7.15(\text{t},1)\text{ppm}$ .

Preparation 39N-[4-(3-Chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]piperazin-2-yl]-  
15 methyl]-4-[(methylsulfonyl)amino]benzamide

In a manner similar to Preparation 3, react 4-(3-chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinemethanamine (3.0 g, 7.9 mmol) with 4-[(methylsulfonyl)amino]benzoyl chloride (2.4 g, 10 mmol) to obtain the title compound.

20 NMR ( $\text{CDCl}_3$ ):  $\delta = 2.85\text{-}3.05(\text{m},3)$ ,  $3.10(\text{s},3)$ ,  $3.30\text{-}3.52(\text{m},4)$ ,  $3.72\text{-}3.92(\text{m},8)$ ,  $4.02(\text{d},2)$ ,  $6.75\text{-}6.92(\text{m},6)$ ,  $7.15(\text{t},1)$ ,  $7.26(\text{d},2)$  and  $7.70(\text{d},2)\text{ppm}$ .

Preparation 404-[(Methyl)(methylsulfonyl)amino]-N-[4-phenyl-1-(phenylmethyl)-piperazin-2-yl]methyl]benzamide

To 4-phenyl-1-(phenylmethyl)-2-piperazinemethanamine (6.95 g, 24.7 mmol) in toluene (130 mL) at 0°C add trimethylaluminum (2.0M in toluene, 16.2 mL, 32.4 mmol). Allow the reaction to warm to room temperature and add 4-[(methyl)(methylsulfonyl)amino]benzoic acid methyl ester (6.91 g, 28.4 mmol). Heat the reaction and monitor the progress by thin-layer chromatography. Upon completion make the solution basic with aqueous NaOH and extract with EtOAc. Remove the solvent in vacuo. Flash chromatograph the residue on silica gel with EtOAc/hexane (2/1) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.36(m,1), 2.81(m,2), 2.87-3.10(m,2), 3.02(s,3), 3.24(m,1), 3.31(s,3), 3.35-3.58(m,2), 3.50(d,1), 3.77(m,1), 4.16(d,1), 6.80(t,1), 6.96(d,2), 7.18-7.45-(m,7), 7.55(d,2), 7.91(d,2) and 8.62(t,1)ppm.

Preparation 414-(3-Aminophenyl)-2-piperazinecarboxamide

To methanol add 4-(3-aminophenyl)-1-(phenylmethyl)-2-piperazinecarboxamide and Pd(OH)<sub>2</sub>. Place the reaction on a Parr hydrogenator at 50 psi of H<sub>2</sub> and shake. Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the reaction, remove the catalyst by suction filtration through celite. Remove solvent in vacuo to obtain the title compound.

Preparation 424-(3-Aminophenyl)-2-piperazinecarboxylic acid

5 In a manner similar to Preparation 17, react 4-(3-aminophenyl)-2-piperazinecarboxamide with potassium hydroxide to obtain the title compound.

Preparation 4310 4-(3-Aminophenyl)-2-piperazinemethanol

In a manner similar to Preparation 18, react 4-(3-aminophenyl)-2-piperazinecarboxylic acid with borane dimethylsulfide to obtain the title compound.

15 Preparation 444-(2-Methyl-1H-imidazol-1-yl)benzenemethanol

In a manner similar to Preparation 18, react 4-(2-methyl-1H-imidazol-1-yl)benzoic acid with borane dimethylsulfide complex to obtain the title compound.

Preparation 451-(4-Chloromethylphenyl)-2-methyl-1H-imidazole

To 4-(2-methyl-1H-imidazole-1-yl)benzenemethanol add thionyl chloride.

5 Monitor the progress of the reaction by thin-layer chromatography. Upon completion remove the excess thionyl chloride in vacuo. Partition the residue between 1N NaOH and CH<sub>2</sub>Cl<sub>2</sub>. Separate and dry the organic layer. Remove the solvent in vacuo to obtain the title compound.

10

Preparation 461-(3-Aminophenyl)-3-[[[4-(2-methyl-1H-imidazol-1-yl)phenyl]methoxy]methyl]piperazine

In a manner similar to Preparation 19, react 4-(3-aminophenyl)-2-piperazinemethanol with 1-[4-(chloromethyl)phenyl]-2-methyl-1H-imidazole to obtain the title compound.

Preparation 47N-(3,5-Dichlorophenyl)-2-[(3,4-dimethoxyphenyl)methyl]amino]acetamide

In a manner similar to Preparation 12, react 2-chloro-N-(3,5-dichlorophenyl)acetamide with (3,4-dimethoxyphenyl)methanamine to obtain the title compound.

25

Preparation 48N-(3,5-Dichlorophenyl)-N'-[(3,4-dimethoxyphenyl)methyl]-1,2-ethanediamine

5 In a manner similar to Preparation 2, react N-(3,5-dichlorophenyl)-2-[[(3,4-dimethoxyphenyl)methyl]amino]acetamide with lithium aluminum hydride to obtain the title compound.

Preparation 49

10

4-(3,5-Dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinecarboxamide

In a manner similar to Preparation 1, react N-(3,5-dichlorophenyl)-N'[(3,4-dimethoxyphenyl)methyl]-1,2-ethanediamine with 2,3-dibromopropanamide to obtain the title compound.

15

Preparation 504-(3,5-Dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinecarboxylic acid

20 In a manner similar to Preparation 17, react 4-(3,5-dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinecarboxamide to obtain the title compound.

25

Preparation 514-(3,5-Dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinemethanol

5 In a manner similar to Preparation 18, react 4-(3,5-dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinecarboxylic acid with borane dimethylsulfide complex to obtain the title compound.

Preparation 52

10

4-(3,5-Dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-[[4-nitrophenyl]methoxy]methyl]piperazine

In a manner similar to Preparation 19, react 4-(3,5-dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinemethanol with sodium hydride and 1-chloromethyl)-4-nitrobenzene to give the title compound.  
15

Preparation 53N-[4-[[4-(3,5-Dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]piperazine-2-yl]methoxy]methyl]phenyl]methanesulfonamide

20

In a manner similar to Preparation 27, react 4-(3,5-dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-[[4-nitrophenyl)methoxy]methyl]piperazine to obtain the title compound.  
25

Preparation 54N-(3,5-dimethoxyphenyl)-N'-(phenylmethyl)-1,2-ethanediamine

5 In a manner similar to Preparation 29, react 3,5-dimethoxybenzenamine with N-(2-chloroethyl)benzenemethanamine to obtain the title compound.

Preparation 5510 4-(3,5-Dimethoxyphenyl)-1-(phenylmethyl)-2-piperazinecarboxamide

In a manner similar to Preparation 1, react N-(3,5-dimethoxyphenyl)-N'-(phenylmethyl)-1,2-ethanediamine with 2,3-dibromopropanamide to obtain the title compound.

15 Preparation 56

4-(3,5-Dimethoxyphenyl)-1-(phenylmethyl)-2-piperazinemethanamine

In a manner similar to Preparation 2, react 4-(3,5-dimethoxyphenyl)-1-(phenylmethyl)-2-piperazinecarboxamide with lithium aluminum hydride to obtain  
20 the title compound.

Preparation 57

5                   N-[4-(3,5-Dimethoxyphenyl)-1-(phenylmethyl)piperazin-2-yl]methyl]-4-[(ethylsulfonyl)-  
amino]benzenesulfonamide

In a manner similar to Preparation 3, react 4-(3,5-dimethoxyphenyl)-1-(phenylmethyl)-2-piperazinemethanamine with 4-[(ethylsulfonyl)amino]benzenesulfon chloride to obtain the title compound.

10

Preparation 58

N-(3-Bromo-5-methoxyphenyl)-2-chloroacetamide

In a manner similar to Preparation 3, react 3-bromo-5-methoxybenzeneamine with chloroacetyl chloride to obtain the title compound.

15

Preparation 59

N-(3-Bromo-5-methoxyphenyl)-2-[(3,4-dimethoxyphenyl)methyl]amino]acetamide

20                  In a manner similar to Preparation 12, react N-(3-bromo-5-methoxyphenyl)-2-chloroacetamide with 3,4-dimethoxybenzenemethanamine to obtain the title compound.

25

Preparation 60N-(3-bromo-5-methoxyphenyl)-N'-(3,4-dimethoxyphenyl)methyl]-1,2-ethanediamine

5 In a manner similar to Preparation 2, react N-(3-bromo-5-methoxyphenyl)-2-[(3,4-dimethoxyphenyl)methyl]amino]acetamide with lithium aluminum hydride to obtain the title compound.

Preparation 61

10

4-(3-Bromo-5-methoxyphenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinecarboxamide

In a manner similar to Preparation 1, react N-(3-bromo-5-methoxyphenyl)-N'-(3,4-dimethoxyphenyl)methyl]-1,2-ethanediamine with 2,3-dibromopropanamide to obtain the title compound.

15

Preparation 624-(3-Bromo-5-methoxyphenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinemethanamine

20 In a manner similar to Preparation 2, react 4-(3-bromo-5-methoxyphenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinecarboxamide with lithium aluminum hydride to obtain the title compound.

25

Preparation 634-(1H-Imidazol-1-yl)benzenesulfonyl chloride

To chlorosulfonic acid cooled to 0°C in an ice bath is added portionwise 1-phenyl-1H-imidazole. Monitor the progress of the reaction by thin-layer chromatography. When the reaction is complete, quench the mixture on ice. Saturated aqueous NaHCO<sub>3</sub> is added until the solution is no longer acidic. Extract the mixture with CH<sub>2</sub>Cl<sub>2</sub>. Dry the organic layer over anhydrous Na<sub>2</sub>SO<sub>4</sub> and remove the solvent in vacuo to obtain the title compound.

Preparation 64N-[4-(3-Bromo-5-methoxyphenyl)-1-[(3,4-dimethoxyphenyl)methyl]piperazin-2-yl]-methyl]-4-(1H-imidazol-1-yl)benzenesulfonamide

In a manner similar to Preparation 3, react 4-(3-bromo-5-methoxyphenyl)-1-[(3,4-dimethoxyphenyl)methyl]-2-piperazinemethanamine with 4-(1H-imidazol-1-yl)benzenesulfonyl chloride to obtain the title compound.

20

Preparation 65N-(2,6-Dichlorophenyl)-2-[(3,4-dimethoxyphenyl)methyl]amino]acetamide

In a manner similar to Preparation 12, react 2-chloro-N-(2,6-dichlorophenyl)acetamide with 3,4-dimethoxybenzenemethanamine to obtain the title compound.

Preparation 66N-(2,6-Dichlorophenyl)-N'-[(3,4-dimethoxyphenyl)methyl]-1,2-ethanediamine

5 In a manner similar to Preparation 2, react N-(2,6-dichlorophenyl)-2-  
[(3,4-dimethoxyphenyl)methyl]amino]acetamide with lithium aluminum hydride  
to obtain the title compound.

Preparation 67

10

4-(2,6-Dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-N-(2-propenyl)-2-  
piperazinecarboxamide

In a manner similar to Preparation 23, react N-(2,6-dichlorophenyl)-N'-  
[(3,4-dimethoxyphenyl)methyl]-1,2-ethanediamine with 2,3-dibromo-N-(2-  
15 propenyl)propanamide to obtain the title compound.

Preparation 684-(2,6-Dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-N-(2-propenyl)-2-  
piperazinemethanamine

20 In a manner similar to Preparation 2, react 4-(2,6-dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-N-(2-propenyl)-2-piperazinecarboxamide with lithium aluminium hydride to obtain the title compound.

25

Preparation 69N-[4-(2,6-Dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]piperazin-2-yl]-methyl]-4-[(methylsulfonyl)amino]-N-(2-propenyl)benzenesulfonamide

5 In a manner similar to Preparation 3, react 4-(2,6-dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-N-(2-propenyl)-2-piperazinemethanamine with 4-[(methylsulfonyl)amino]benzenesulfonyl chloride to obtain the title compound.

Preparation 70

10

N-(2-Methoxyethyl)-N-(4-nitrophenyl)-2-propenamide

In a manner similar to Preparation 3, react N-(2-methoxyethyl)-4-nitrobenzenamine with propenoyl chloride to obtain the title compound.

15

Preparation 712,3-Dibromo-N-(2-methoxyethyl)-N-(4-nitrophenyl)propanamide

In a manner similar to Preparation 22, react N-(2-methoxyethyl)-N-(4-nitrophenyl)propanamide with bromine to obtain the title compound.

20

Preparation 72N-(4-Ethoxyphenyl)-N'-(phenylmethyl)-1,2-ethanediamine

In a manner similar to Preparation 29, react 4-ethoxybenzenamine with N-(2-chloroethyl)benzenemethanamine to obtain the title compound.

Preparation 734-(4-Ethoxyphenyl)-N-(2-methoxyethyl)-N-(4-nitrophenyl)-1-(phenylmethyl)-2-piperazinecarboxamide

5 In a manner similar to Preparation 23, react N-(4-ethoxyphenyl)-N-(phenylmethyl)-1,2-ethanediamine with 2,3-dibromo-N-(2-methoxyethyl)-N-(4-nitrophenyl)propanamide to obtain the title compound.

Preparation 74

10 N-(4-Aminophenyl)-4-(4-ethoxyphenyl)-N-(2-methoxyethyl)-1-(phenylmethyl)-2-piperazinecarboxamide

In a manner similar to Preparation 20, react 4-(4-ethoxyphenyl)-N-(2-methoxyethyl)-N-(4-nitrophenyl)-1-(phenylmethyl)-2-piperazinecarboxamide with  
15 tin II chloride to obtain the title compound.

Preparation 75

20 4-(4-Ethoxyphenyl)-N-(2-methoxyethyl)-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-1-(phenylmethyl)-2-piperazinecarboxamide

In a manner similar to Preparation 34, react N-(4-aminophenyl)-4-(4-ethoxyphenyl)-N-(2-methoxyethyl)-1-(phenylmethyl)-2-piperazinecarboxamide with glyceraldehyde, acetaldehyde and ammonium hydroxide to obtain the title compound.

Preparation 76

4-(4-Ethoxyphenyl)-N-(2-methoxyethyl)-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-1-(phenylmethyl)-2-piperazinemethanamine

5 In a manner similar to Preparation 2, react 4-(4-ethoxyphenyl)-N-(2-methoxyethyl)-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-1-(phenylmethyl)-2-piperazinecarboxamide with lithium aluminum hydride to obtain the title compound.

10

Preparation 77

4-(3-Chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-N-(1-methylethyl)-2-piperazinecarboxamide

15 In a manner similar to Preparation 23, react N-(3-chlorophenyl)-N'-(3,4-dimethoxyphenyl)methyl]-1,2-ethanediamine with 2,3-dibromo-N-(1-methylethyl)-propanamide to obtain the title compound.

Preparation 78

20 4-(3-Chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-N-(1-methylethyl)-2-piperazinemethanamine

In a manner similar to Preparation 2, react 4-(3-chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-N-(1-methylethyl)-2-piperazinecarboxamide with lithium aluminum hydride to obtain the title compound.

25

Preparation 79N-[4-(3-Chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]piperazin-2-yl]methyl]-N-(1-methylethyl)-4-[(methylsulfonyl)amino]benzamide

5        In a manner similar to Preparation 3, react 4-(3-chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]-N-(1-methylethyl)-2-piperazinemethanamine with 4-[(methylsulfonyl)amino]benzoyl chloride to obtain the title compound.

Preparation 80

10

1-(3,4-Dichlorophenyl)-4-(1,1-dimethylethyl)-2-piperazinecarbonitrile

In a manner similar to preparation 1, react N-(3,4-dichlorophenyl)-N'-(1,1-dimethoxyethyl)-1,2-ethanediamine with 2,3-dibromopropanenitrile to obtain the title compound.

15

Preparation 811-(3,4-Dichlorophenyl)-4-(1,1-dimethylethyl)-2-piperazinemethanamine

20        In a manner similar to preparation 2, react 1-(3,4-dichlorophenyl)-4-(1,1-dimethylethyl)-2-piperazinecarbonitrile with lithium aluminum hydride to obtain the title compound.

25

Preparation 821-Methyl-4-phenyl-2-piperazinecarboxamide

5 In a manner similar to preparation 1, react N-methyl-N'-phenyl-1,2-ethanediamine with 2,3-dibromopropanamide to obtain the title compound.

Preparation 83

10

1-Methyl-4-phenyl-2-piperazinemethanamine

In a manner similar to preparation 2, react 1-methyl-4-phenyl-2-piperazinecarboxamide with lithium aluminum hydride to obtain the title compound.

15

Preparation 844-Butyl-1-(3,4-dimethoxyphenyl)-2-piperazinecarbonitrile

20 In a manner similar to preparation 1, react N-butyl-N'-(3,4-dimethoxyphenyl)-1,2-ethanediamine with 2-chloro-2-propenenitrile to obtain the title compound.

25

Preparation 854-Butyl-1-(3,4-dimethoxyphenyl)-2-piperazinemethanamine

In a manner similar to preparation 2, react 4-butyl-1-(3,4-dimethoxyphenyl)-2-piperazinecarbonitrile with lithium aluminum hydride to obtain the title compound.

Preparation 864-(3,4-Dichlorophenyl)-1-ethyl-N-(4-nitrophenyl)-2-piperazinecarboxamide

In a manner similar to preparation 23, react N-(3,4-dichlorophenyl)-N'-ethyl-1,2-ethanediamine with 2,3-dibromo-N-(4-nitrophenyl)propanamide to obtain the title compound.

15

Preparation 87N-(4-Aminophenyl)-4-(3,4-dichlorophenyl)-1-ethyl-2-piperazinecarboxamide

In a manner similar to preparation 20, react 4-(3,4-dichlorophenyl)-1-ethyl-N-(4-nitrophenyl)-2-piperazinecarboxamide with tin II chloride to obtain the title compound.

Preparation 884-(3,4-Dichlorophenyl)-1-ethyl-N-[4-(1H-imidazol-1-yl)phenyl]-2-piperazinecarboxamide

25 In a manner similar to preparation 34, react N-(4-aminophenyl)-4-(3,4-

dichlorophenyl)-1-ethyl-2-piperazinecarboxamide, ammonium hydroxide, aqueous formaldehyde, and glyoxal to obtain the title compound.

### EXAMPLES

5

#### Example 1

##### 4-[(Methylsulfonyl)amino]-N-[4-phenylpiperazin-2-yl)methyl]benzamide hydrochloride

10 To methanol (400 mL) add 4-[(methylsulfonyl)amino]-N-[4-phenyl-1-(phenylmethyl)piperazin-2-yl)methyl]benzamide hydrochloride (40 g, 77 mmol) and Pd(OH)<sub>2</sub> (2.0 g). When the addition is complete, place the reaction mixture on a Parr hydrogenator at 50 p.s.i. of H<sub>2</sub> and shake. Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the reaction, remove 15 the catalyst by suction filtration through celite. Wash the pad with methanol. Remove the solvent in vacuo to obtain a residue. Recrystallize from methanol to provide the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.98(dd,1), 3.07(s,3), 3.1(m,1), 3.3-3.9(m,7), 6.87(t,1), 7.00(d,2), 7.3(m,4), 7.97(d,2), 8.88(t,1), 9.54(br,2) and 10.2(br,1)ppm.

20

25

Example 2N-[4-[[[(4-Phenylpiperazin-2-yl)methyl]amino]methyl]phenyl]methanesulfonamide,sulfuric acid salt

To 4-[(methylsulfonyl)amino]-N-[(4-phenylpiperazin-2-yl)methyl]benzamide (3.2 g, 8.2 mmol) in tetrahydrofuran (10 mL) add borane dimethylsulfide (2.5 mL, 25 mmol). Stir and heat the reaction under nitrogen at reflux. Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the reaction, add methanolic hydrochloric acid dropwise. Continue to reflux the reaction for 2 h. Remove the solvent in vacuo. Dissolve the material in methanol/H<sub>2</sub>O and add the ion exchange resin AG 1-X8 until the pH is 8. The resin is removed by filtration and remove the solvent in vacuo. Dissolve the residue in methanol and add concentrated H<sub>2</sub>SO<sub>4</sub> (0.23 mL, 4.3 mmol) to give the title compound which precipitates from the solution.

NMR (DMSO-d<sub>6</sub>): δ = 2.65(t,1), 2.7-2.9(m,3), 2.98(s,3), 3.00(m,1), 3.26(m,2), 3.6(d,1), 3.7(d,1), 3.81(d,1), 3.84(d,1), 4.0(br s,2), 6.84(t,1), 6.97(t,2), 7.19(d,2), 7.26(d,2), 7.39(d,2) and 9.8(br,1)ppm.

Example 3

20

4-[(Methylsulfonyl)amino]-N-[(1-phenylpiperazin-2-yl)methyl]benzamide

To methanol (500 mL) under nitrogen atmosphere add 4-[(methylsulfonyl)amino]-N-[1-phenyl-4-(phenylmethyl)piperazin-2-yl]methyl]benzamide (10.4 g, 21.7 mmol), ammonium formate (27.4 g, 4.34 mmol) and Pd/C (1.0 g) and reflux. Monitor the progress of the reaction by thin-layer chromatography.

Upon completion of the reaction, remove the catalyst by suction filtration through celite. Wash the pad with methanol. Remove the solvent in vacuo. Add water to the residue and adjust the pH to 8.5 with dilute sodium hydroxide solution. Extract the mixture with methylene chloride/2-propanol (9/1). Repeat 5 this extraction two times. Concentrate the organic layers to give a white solid. Recrystallize from acetonitrile/methanol to provide the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.75(m,2), 3.00(m,3), 3.07(s,3), 3.30(m,2), 3.68(m,1), 3.95(m,1), 6.69(t,1), 7.00(d,2), 7.21(m,4), 7.45(d,2) and 8.46(t,1)ppm.

10

Example 44-(1H-Imidazol-1-yl)-N-[4-phenylpiperazin-2-yl)methyl]benzamidetrihydrochloride

In a manner similar to Example 1, react 4-(1H-imidazol-1-yl)-N-[4-phenyl-1-(phenylmethyl)piperazin-2-yl]methyl]benzamide trihydrochloride (12.3 g, 15 22 mmol) with H<sub>2</sub> over Pd(OH)<sub>2</sub> (1.5 g) catalyst to give the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 3.2(m,3), 3.44(m,1), 3.56-3.94(m,5), 4.7-6.2(br, 2+H<sub>2</sub>O), 6.90(t,1), 7.06(d,2), 7.20(m,2), 8.02(m,3), 8.28(d,2), 8.46(s,1), 9.31(t,1) and 9.84-10.14(m,3)ppm.

20

25

Example 55           N-[4-(3-Methoxyphenyl)piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]-  
benzamide dihydrochloride

In a manner similar to Example 1, react 4-[(methylsulfonyl)amino]-N-[4-(3-methoxyphenyl)-1-(phenylmethyl)piperazin-2-yl]methyl]benzamide dihydrochloride (2.3 g, 4 mmol) with H<sub>2</sub> over Pd(OH)<sub>2</sub> (0.3 g) catalyst to give the title compound.

10           NMR (DMSO-d<sub>6</sub>): δ = 3.00-3.30(m,3), 3.08(s,3), 3.40(d,1), 3.50-3.90(m,4),  
3.73(s,3), 6.49(dd,1), 6.54-6.66(m,2), 7.19(t,1), 7.30(d,2), 8.00(d,2), 8.25(br s,2),  
8.95(t,1), 9.60-9.90(m,2), 10.27(s,1)ppm.Example 615           N-[4-(2-Methoxyphenyl)piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]benzamide  
hydrochloride

In a manner similar to Example 1, react N-[4-(2-methoxyphenyl)-1-(phenylmethyl)piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]benzamide hydrochloride (8.7 g, 16 mmol) with H<sub>2</sub> over Pd(OH)<sub>2</sub> (0.2 g) catalyst to give the title compound.

20           NMR (DMSO-d<sub>6</sub>): δ = 2.9(dd,1), 3.07(s,3), 3.0-3.2(m,4), 3.3-3.7(m,5),  
3.74(s,3), 3.8(m,1), 6.8-7.1(m,4), 7.29(d,2), 7.95(d,2), 8.85(t,1), 9.6(br,2) and  
10.2(br,1)ppm.

Example 7N-[4-[(4-Phenylpiperazin-2-yl)methoxy]phenyl]methanesulfonamide hydrochloride

5 In a manner similar to Example 1, hydrogenolyze N-[4-[[4-phenyl-1-(phenyl-methyl)piperazin-2-yl]methoxy]phenyl]methanesulfonamide hydrochloride (7.4 g, 15 mmol) to give the title compound.

NMR (DMSO-d<sub>6</sub>): δ 2.90(s,3), 3.1(m,3), 3.4(m,1), 3.75(m,2), 3.91(m,1), 4.28(m,2), 6.86(t,1), 7.03(m,4), 7.22(m,4), 9.51(s,1) and 9.65(br s,2)ppm.

10

Example 8N-[4-[[4-Phenylpiperazin-2-yl)methyl]amino]phenyl]methanesulfonamide

15 In a manner similar to Example 1, react N-[4-[[[4-phenyl-1-(phenylmethyl)piperazin-2-yl]methyl]amino]phenyl]methanesulfonamide hydrochloride (2.05 g, 4.22 mmol) with H<sub>2</sub> over 10% palladium on activated carbon (0.19 g). Remove the catalyst by filtration and evaporate the solvent. Dissolve the residue in methanol and adjust the pH to 8 with 4M aqueous NaOH. Remove the solvent in vacuo. Triturate the residue with methylene chloride. Remove the solid by filtration. Recrystallize the residue from methylene chloride to obtain the title compound.

20 NMR (DMSO-d<sub>6</sub>): δ = 2.61(dd,1), 2.82(td,1), 2.93(s,3), 3.04(td,1), 3.11-3.35(m,4), 3.56(m,2), 4.18(br s,1), 6.08(br,1), 6.65(d,2), 6.91(t,1), 6.97(d,2), 7.12(d,2) and 7.30(m,2)ppm.

25

Example 9N-[4-[(1-Phenylpiperazin-2-yl)methyl]amino]phenyl]methanesulfonamide

In a manner similar to Example 1, react N-[4-[[[1-phenyl-4-(phenylmethyl)piperazin-2-yl]methyl]amino]phenyl]methanesulfonamide, hydrochloride (2.92 g, 6.0 mmol) with H<sub>2</sub> over 10% palladium on activated charcoal (0.29 g). Chromatograph the residue on silica with CH<sub>3</sub>CN/NH<sub>4</sub>OH (99/1) to obtain the title compound.

NMR (CDCl<sub>3</sub>): δ = 2.89(s,3), 2.96(m,1), 3.05-3.32(m,6), 3.46(m,1), 3.90(m,1), 4.12(br,1), 6.44(d,2), 6.87(t,1), 6.93(d,2), 7.02(d,2) and 7.26(m,2)ppm.

Example 10N-[[4-[3-(1H-Imidazol-1-yl)phenyl]piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]

benzamide, hydrochloride

In a manner similar to Example 1, react N-[[4-[3-(1H-imidazol-1-yl)phenyl]-1-(phenylmethyl)piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]benzamide hydrochloride (2.5 g, 4.4 mmol) with H<sub>2</sub> over Pd on carbon (1.2 g) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 3.01(m,1), 3.07(s,3), 3.15(m,2), 3.52(m,2), 3.65(m,2), 3.86(m,1), 3.98(d,1), 6.99(dd,1), 7.11(dd,1), 7.12(s,1), 7.25(d,2), 7.29(s,1), 7.39(t,1), 7.77(s,1), 7.94(d,2), 8.30(s,1), 8.80(t,1), 9.4(br,2) and 10.2(br s,1)ppm.

Example 11N-[[4-(3-Chlorophenyl)piperazin-2-yl]methyl]-4-[(methylsulfonyl)-  
amino]benzamide

To a 5% solution of concentrated sulfuric acid in anhydrous trifluoroacetic acid (12 mL) under nitrogen atmosphere, add 4-[(methylsulfonyl)amino]-N-[4-(3-chlorophenyl)-1-(3,4-dimethoxyphenylmethyl)piperazin-2-yl]methyl]benzamide (2.6 g, 5 mmol) and methoxybenzene (1.1 g, 10 mmol) and heat at 60°C. Monitor the progress of the reaction by thin-layer chromatography. Upon completion of the reaction add water (5 mL), 1N NaOH (10 mL) and saturated NaHCO<sub>3</sub> (10 mL) and extract this mixture with methylene chloride. Concentrate the organic layer. Flash chromatograph the oil on silica (100 g) with acetonitrile first, then a mixture of acetonitrile/methanol (85/15). Combine and concentrate the fractions containing product. Dissolve the oil in methanol and add a solution of hydrogen chloride in methanol. Remove the solvent in vacuo and recrystallize from acetonitrile/methanol to provide the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.95-3.22(m,2), 3.07(s,3), 3.32-3.55(m,2), 3.58-3.92(m,5), 6.90(d,1), 7.07(d,1), 7.24(s,1), 7.28(m,3), 7.96(d,2), 8.87(t,1), 9.38-9.68(m,2), and 10.22(s,1)ppm.

20

Example 124-[(Methyl)(methylsulfonyl)amino]-N-[(4-phenylpiperazin-2-yl)methyl]benzamide, hydro-  
chloride In a manner similar to Example 1, react 4-[(methyl)(methylsulfonyl)-

25 amino]-N-[4-phenyl-1-(phenylmethyl)piperazin-2-yl]methyl]benzamide,

dihydrochloride (8.0 g, 14.2 mmol) with H<sub>2</sub> over 10% palladium on carbon (0.7 g) to obtain the title compound.

NMR (DMSO-d<sub>6</sub>): δ = 2.90(m,1), 2.99(s,3), 2.98-3.20(m,2), 3.28(s,3), 3.4(m,2), 3.55-3.75(m,3), 3.80(m,1), 6.84(t,1), 7.01(d,2), 7.26(t,2), 7.53(d,2), 5 7.95(d,2), 8.82(t,1) and 9.0(br,2)ppm.

Example 13

1-[3-(1H-Imidazol-1-yl)phenyl]-3-[[[4-(2-methyl-1H-imidazol-1-yl)phenyl]methoxy]-10 methyl]piperazine

In a manner similar to Preparation 34, react 1-(3-aminophenyl)-3-[[[4-(2-methyl-1H-imidazol-1-yl)phenyl]methoxy]methyl]piperazine with glyoxal, formaldehyde, and ammonium acetate to obtain the title compound.

Example 14

N-[4-[[[4-(3,5-Dichlorophenyl)piperazin-2-yl]methoxy]methyl]phenyl]methanesulfonamide

In a manner similar to Example 11, react N-[4-[[[4-(3,5-dichlorophenyl)-1-20 [(3,4-dimethoxyphenyl)methyl]piperazin-2-yl]methoxy]methyl]phenyl]methane-sulfonamide with methoxybenzene and a 5% solution of concentrated H<sub>2</sub>SO<sub>4</sub> in trifluoroacetic acid to obtain the title compound.

Example 15

N-[[4-(3,5-Dimethoxyphenyl)piperazin-2-yl]methyl]-4-[(ethylsulfonyl)amino]-benzenesulfonamide

5 In a manner similar to Example 1, hydrogenolyze N-[[4-(3,5-dimethoxyphenyl)-1-(phenylmethyl)piperazin-2-yl]methyl]-4-[(ethylsulfonyl)amino]-benzenesulfonamide over Pd(OH)<sub>2</sub> to obtain the title compound.

Example 16

10

N-[[4-(3-Bromo-5-methoxyphenyl)piperazin-2-yl]methyl]-4-(1H-imidazol-1-yl)-benzenesulfonamide

In a manner similar to Example 11, react N-[[4-(3-bromo-5-methoxyphenyl)-1-[(3,4-dimethoxyphenyl)methyl]piperazin-2-yl]methyl]-4-(1H-imidazol-1-yl)benzenesulfonamide with methoxybenzene and a 5% solution of concentrated H<sub>2</sub>SO<sub>4</sub> in trifluoroacetic acid to obtain the title compound.

Example 17

20

N-[[4-(2,6-Dichlorophenyl)piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]-N-(2-propenyl)benzenesulfonamide

In a manner similar to Example 11, react N-[[4-(2,6-dichlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]-N-(2-propenyl)benzenesulfonamide with methoxybenzene and a 5% solution of concentrated H<sub>2</sub>SO<sub>4</sub> in trifluoroacetic acid to obtain the title compound.

Example 18

4-(4-Ethoxyphenyl)-N-(2-methoxyethyl)-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-2-piperazinemethanamine

5 In a manner similar to Example 1, hydrogenolyze 4-(4-ethoxyphenyl)-N-(2-methoxyethyl)-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-1-(phenylmethyl)-2-piperazinemethanamine over Pd(OH)<sub>2</sub> to obtain the title compound.

Example 19

10

N-[[4-(3-Chlorophenyl)piperazin-2-yl]methyl]-N-(1-methylethyl)-4-[(methylsulfonyl)amino]benzamide

In a manner similar to Example 11, react N-[[4-(3-chlorophenyl)-1-[(3,4-dimethoxyphenyl)methyl]piperazin-2-yl]methyl]-N-(1-methylethyl)-4-[(methylsulfonyl)amino]benzamide with methoxybenzene and a 5% solution of concentrated H<sub>2</sub>SO<sub>4</sub> in trifluoroacetic acid to obtain the title compound.

Example 20

20

N-[[1-(3,4-Dichlorophenyl)-4-(1,1-dimethylethyl)piperazin-2-yl]methyl]-4-(1H-imidazol-1-yl)benzamide

In a manner similar to preparation 7, react 4-(1H-imidazol-1-yl)benzoic acid, 1,1-carbonyldiimidazole and 1-(3,4-dichlorophenyl)-4-(1,1-dimethylethyl)-2-piperazinemethanamine to obtain the title compound.

25

Example 21N-[(1-Methyl-4-phenylpiperazin-2-yl)methyl]-4-[(methylsulfonyl)amino]benzamide

In a manner similar to preparation 3, react 1-methyl-4-phenyl-2-piperazinemethanamine with 4-[(methylsulfonyl)amino]benzoyl chloride to obtain the title compound.

Example 22

10      N-[[4-Butyl-1-(3,4-dimethoxyphenyl)piperazin-2-yl]methyl]-4-[(methylsulfonyl)amino]benzenesulfonamide

In a manner similar to preparation 3, react 4-butyl-1-(3,4-dimethoxyphenyl)-2-piperazinemethanamine with 4-[(methylsulfonyl)amino]sulfonyl chloride to obtain the title compound.

15

Example 234-(3,4-Dichlorophenyl)-1-ethyl-N-[4-(1H-imidazol-1-yl)phenyl]-2-piperazinemethanamine

In a manner similar to preparation 2, react 4-(3,4-dichlorophenyl)-1-ethyl-N-[4-(1H-imidazol-1-yl)phenyl]-2-piperazinecarboxamide with lithium aluminum hydride to obtain the title compound.

25


CLAIMS

5        We claim:

-1-

A compound of the following Formula I:

10




15

wherein

R is hydrogen, lower alkyl or benzyl;

R<sub>1</sub> and R<sub>2</sub> are the same or independently hydrogen, lower alkyl, lower  
20        alkoxy or halogen;Z is  $\text{NR}_3\text{C=O}$ ,  $\text{NR}_3\text{CH}_2$ ,  $\text{OCH}_2$ ,  $\text{NR}_3$ ,  $\text{O}^-$  or  $\text{NR}_3\text{SO}_2^-$  ;Q is  $(\text{C}_1\text{--C}_4)\text{SO}_2\text{NR}_4^-$  or

25




R<sub>3</sub> is hydrogen, lower alkyl, allyl, loweralkoxyloweralkyl;

R<sub>4</sub> is hydrogen or methyl;

and the pharmaceutically acceptable salts thereof;

5 provided that,

when R<sub>4</sub> is methyl then




must be in the ② postion of Formula I.

10

-2-


A compound of claim 1 where R and R<sub>4</sub> are hydrogen and



15

-3-

A compound of claim 1 where R and R<sub>4</sub> are hydrogen and



20

-4-


A compound of claim 1 where R is not hydrogen and R<sub>4</sub> is hydrogen.

25

-5-

A compound of claim 1 where R is hydrogen and R<sub>4</sub> is methyl and

5



-6-

A compound of claim 2 which is N-[4-[[[(4-phenylpiperazin-2-yl)methyl]-amino]methyl]phenyl]methanesulfonamide.

10

-7-

A compound of claim 2 which is N-[4-[(4-phenylpiperazin-2-yl)methyl]-amino]phenyl]methanesulfonamide.

15

-8-

A compound of claim 2 which is 4-[(methylsulfonyl)amino]-N-[(4-phenylpiperazin-2-yl)methyl]benzamide.

20

-9-

A compound of claim 2 which is 4-(1H-imidazol-1-yl)-N-[(4-phenylpiperazin-2-yl)methyl]benzamide.

25

-10-

A compound of claim 2 which is N-[[4-(3-methoxyphenyl)piperazin-2-yl]-methyl]-4-[(methylsulfonyl)amino]benzamide.

-11-

A compound of claim 2 which is N-[[4-(2-methoxyphenyl)piperazin-2-yl]-methyl]-4-[(methylsulfonyl)amino]benzamide.

5

8

-12-

A compound of claim 2 which is N-[4-[(4-phenylpiperazin-2-yl)methoxy]-phenyl]methanesulfoxamide.

10

-13-

A compound of claim 2 which is N-[[4-(3-chlorophenyl)piperazin-2-yl]-methyl]-4-[(methylsulfonyl)amino]benzamide.

15

-14-

A compound of claim 3 which is 4-[(methylsulfonyl)amino]-N-[(1-phenyl-piperazin-2-yl)methyl]benzamide.

20

-15-

A compound of claim 3 which is N-[4-[[1-phenylpiperazin-2-yl)methyl]-amino]phenyl]methanesulfonamide.

25

-16-

A compound of claim 5 which is 4-[(methyl)(methylsulfonyl)amino]-N-[(4-phenylpiperazin-2-yl)methyl]benzamide.

1  
2 -17-


A pharmaceutical composition comprising at least one compound  
according to claim 1, together with one or more non-toxic pharmaceutically  
acceptable carriers.

3  
4 5

-18-

A regioselective process wherein a compound of the following Formula  
II;

10




15


20

wherein Ar is phenyl or 3,4-dimethoxyphenyl and R<sub>1</sub> and R<sub>2</sub> have the same  
meanings as in Claim 1, is reacted with about 2 equivalents of 2,3-  
dibromopropanamide or 2,3-dibromopropanecarbonitrile in an inert aprotic solvent  
in the presence of base at a temperature range of from about 80°C to about  
25      150°C to produce compounds of the following Formulae III and IV respectively.

74



III



IV

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 90/01059

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC  
 Int.C1. 5 C07D241/04 ; C07D403/12 ; A61K31/495

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.C1. 5	C07D ; A61K

Documentation Searched other than Minimum Documentation  
 to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>

III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	EP,A,0332570 (SCHERING) 13 September 1989 see abstract ---	
A	EP,A,0306440 (SCHERING) 08 March 1989 see claim 1 ---	
A	EP,A,0257864 (PFIZER LTD) 02 March 1988 see abstract ---	

\* Special categories of cited documents :<sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

17 OCTOBER 1990


Date of Mailing of this International Search Report

09.11.90

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer



H. Balasteros

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. *PO/EP 90/01054*

SA 38951

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29/10/90

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0332570	13-09-89	US-A-	4906634	06-03-90
EP-A-0306440	08-03-89	US-A-	4851526	25-07-89
EP-A-0257864	02-03-88	JP-A- US-A-	63044572 4797401	25-02-88 10-01-89